Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation.
Inflammation arises in the CNS from a number of neurodegenerative and oncogenic disorders, as well as from ischemic and traumatic brain injuries. These pathologies give rise to increased levels of extracellular adenine nucleotides which, via activation of a variety of cell surface P2 purinergic receptors, influence the inflammatory activities of responding immune cells. One P2 receptor subtype in particular, the P2X(7) receptor, potentiates the release of pro-inflammatory cytokines, such as interleukin-1beta (IL-1beta) from macrophage-like cells. It is also thought to contribute to secondary brain injury by inducing neuronal cell death. Therefore, antagonism of this receptor could have significant therapeutic impact on all disorders, not just CNS, to which excessive inflammatory activities contribute. The use of currently available P2X(7) receptor antagonists for the treatment of CNS inflammation has been limited to the generally non-selective antagonists PPADS, oxidized ATP, Brilliant Blue G, suramin, calmidizolium, and KN-62. However, the recent patents and development of novel P2X(7) receptor antagonists, as discussed in this review, will provide new tools both for clinical and research purposes. Here we discuss compounds for which patents have been applied since 2006, from the following categories: benzamide inhibitors, bicycloheteroaryl compounds, acylhdranzine antagonists, biaromatic P2X(7) antagonists, heterocyclic compounds and amide derivatives, and aromatic amine antagonists.
Friedle
Scott A
SA
Program in Cellular and Molecular Biology and Department of Comparative Biosciences, University of Wisconsin, Madison, WI 53706, USA.
Curet
Marjorie A
MA
Watters
Jyoti J
JJ
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000627:therapeutic use*; D004660:Encephalitis / Q000188:drug therapy*; D006801:Humans; D009187:Myelitis / Q000188:drug therapy*; D010330:Patents as Topic; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D058486:Receptors, Purinergic P2X7
D000893:Anti-Inflammatory Agents; C546468:P2RX7 protein, human; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7
J Biol Chem. 2009 Jul 3;284(27):18143-51
19416975
BMC Cancer. 2006 Sep 23;6:226
16995949
Exp Mol Med. 2007 Dec 31;39(6):820-7
18160853
Proc Natl Acad Sci U S A. 2009 May 12;106(19):8032-7
19380717
Arch Biochem Biophys. 1990 Aug 1;280(2):263-8
2369117
J Biol Chem. 2005 Sep 16;280(37):32459-67
16030017
J Med Chem. 2008 May 22;51(10):3030-4
18438986
Curr Biol. 2000 Apr 20;10(8):R305-7
10801405
Med Sci Monit. 2001 Jul-Aug;7(4):669-74
11433193
J Biol Chem. 2007 Jan 26;282(4):2386-94
17121814
Neuropharmacology. 1997 Sep;36(9):1295-301
9364484
J Mol Cell Cardiol. 2005 Dec;39(6):929-39
16242142
Neuroscience. 2009 Feb 6;158(3):1122-32
18848864
J Neurosci. 2000 Apr 15;20(8):2835-44
10751435
Am J Physiol. 1999 Jan;276(1):C267-78
9886943
Pharmacol Rev. 2001 Mar;53(1):107-18
11171941
J Biol Chem. 2009 May 15;284(20):13446-13454
19304656
Biomed Pharmacother. 1989;43(10):727-36
2701287
J Neurochem. 2008 Jul;106(1):271-80
18384650
Am J Physiol Renal Physiol. 2002 Apr;282(4):F763-75
11880338
Br J Pharmacol. 1994 Jul;112(3):946-50
7921625
Cancer Res. 2006 Jan 15;66(2):907-14
16424024
Annu Rev Physiol. 2009;71:333-59
18851707
Cancer Lett. 2003 Aug 20;198(2):211-8
12957360
J Comp Neurol. 2008 Jan 1;506(1):75-92
17990272
Curr Drug Targets CNS Neurol Disord. 2003 Dec;2(6):403-12
14683468
BMC Neurol. 2006 Mar 02;6:12
16512913
PLoS One. 2008 Jul 09;3(7):e2599
18612415
Expert Opin Ther Targets. 2008 May;12(5):647-61
18410246
J Neurosci. 1998 Nov 1;18(21):8794-804
9786986
J Neurosci. 2007 Aug 29;27(35):9525-33
17728465
J Med Chem. 2009 May 28;52(10):3123-41
19191585
J Immunol. 2006 Apr 1;176(7):3877-83
16547218
Neuroreport. 1996 Nov 4;7(15-17):2533-7
8981418
Neuroscience. 2005;134(1):199-205
15964696
J Immunol. 2000 Oct 15;165(8):4615-23
11035104
J Cell Physiol. 2006 Oct;209(1):172-82
16826604
Glia. 2005 Jan 15;49(2):245-58
15472991
Neurosci Lett. 1999 Jul 23;270(1):25-8
10454137
J Immunol. 1996 Feb 15;156(4):1531-9
8568257
J Biol Chem. 1987 Mar 5;262(7):3118-22
2950094
J Physiol. 1996 Nov 15;497 ( Pt 1):53-66
8951711
Am J Physiol Cell Physiol. 2001 Jan;280(1):C81-9
11121379
Pharmacology. 2000 Feb;60(2):105-12
10657760
Cell Death Differ. 1998 Mar;5(3):191-9
10200464
Neurobiol Dis. 2007 Jan;25(1):8-16
17045808
J Neurosci. 2007 May 2;27(18):4957-68
17475804
Br J Pharmacol. 2007 Jul;151(5):571-9
17471177
Immunity. 2003 Sep;19(3):403-12
14499115
Mol Pharmacol. 2000 Jul;58(1):82-8
10860929
Am J Med Genet B Neuropsychiatr Genet. 2006 Jun 5;141B(4):374-82
16673375
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15735-40
9861039
Pharmacol Rev. 1998 Sep;50(3):413-92
9755289
Eur J Pharmacol. 2002 Jul 5;447(2-3):261-9
12151017
Physiol Rev. 2007 Apr;87(2):659-797
17429044
Trends Neurosci. 2006 May;29(5):257-62
16564580
J Neuroimmunol. 2004 Feb;147(1-2):56-61
14741428
J Biol Chem. 1990 Mar 15;265(8):4315-20
2155222
Mol Pharmacol. 1995 Aug;48(2):178-83
7544432
Mol Pharmacol. 2007 Dec;72(6):1447-56
17785580
Curr Mol Med. 2009 Mar;9(2):186-94
19275626
J Cell Biochem. 1995 Mar;57(3):452-64
7768980
J Pharmacol Exp Ther. 2006 Dec;319(3):1376-85
16982702
BJU Int. 2004 Jun;93(9):1344-8
15180635
Glia. 2007 Dec;55(16):1648-55
17849469
J Neurosci. 2001 Apr 1;21(7):2215-23
11264297
Curr Top Med Chem. 2004;4(16):1707-17
15579103
Brain Res Bull. 2003 Apr 15;60(1-2):93-104
12725897
Nat Med. 2004 Aug;10(8):821-7
15258577
J Cell Physiol. 1984 May;119(2):211-9
6715419
Nature. 2006 Aug 3;442(7102):527-32
16885977
Eur J Pharmacol. 1999 Jul 2;376(1-2):127-38
10440098
Physiol Rev. 2002 Oct;82(4):1013-67
12270951
Jpn J Pharmacol. 1998 Oct;78(2):113-45
9829617
Neuroscience. 2007 Jun 8;146(4):1817-28
17478048
J Immunol. 2002 Jun 15;168(12):6436-45
12055263
Nat Rev Drug Discov. 2008 Jul;7(7):575-90
18591979
J Med Chem. 2006 Jun 15;49(12):3659-66
16759108
J Biol Chem. 2000 Sep 15;275(37):29107-12
10869366
Int Rev Cytol. 2004;240:31-304
15548415
Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):102-9
10048594
Nature. 1994 Oct 6;371(6497):516-9
7523951
J Biol Chem. 2007 Dec 28;282(52):37350-8
17962183
Am J Physiol Renal Physiol. 2004 Nov;287(5):F1084-91
15251862
J Neurosci. 2008 Oct 29;28(44):11263-8
18971468
EMBO J. 2006 Nov 1;25(21):5071-82
17036048
Biochim Biophys Acta. 1992 Feb 19;1134(1):31-45
1311958
Br J Pharmacol. 2000 Jul;130(6):1418-24
10903985
J Neurosci. 2006 Feb 1;26(5):1378-85
16452661
J Neurosci. 1999 Jan 15;19(2):520-8
9880572
Biochem Biophys Res Commun. 1989 Dec 29;165(3):1279-85
2610693
Br J Pharmacol. 1999 Nov;128(6):1199-206
10578132
Biochimie. 2000 Apr;82(4):289-302
10865118
Brain Res. 1997 Sep 26;769(2):281-6
9374196
Br J Pharmacol. 2006 Dec;149(7):880-7
17031385
J Neurosci. 2004 Jul 14;24(28):6307-14
15254086
J Neurosci. 2008 Sep 10;28(37):9133-44
18784294
Mol Pain. 2009 Apr 23;5:20
19389225
Curr Med Chem. 2007;14(14):1505-23
17584060
Br J Pharmacol. 1998 Jul;124(6):1314-20
9720806
J Immunol. 2008 Jun 1;180(11):7147-57
18490713
J Biol Chem. 1990 May 5;265(13):7424-31
1692021
J Cereb Blood Flow Metab. 1996 Nov;16(6):1137-42
8898685
J Pharmacol Exp Ther. 2001 Mar;296(3):947-57
11181928
Trans Am Clin Climatol Assoc. 2007;118:199-208
18528503
J Neuropathol Exp Neurol. 2006 Nov;65(11):1090-7
17086106
J Neurosci. 2001 Sep 15;21(18):7135-42
11549724
Clin Exp Hypertens. 1999 May;21(4):299-332
10369378
Clin Exp Immunol. 2007 Jun;148(3):469-77
17493019
Nat Neurosci. 2005 Jun;8(6):752-8
15895084
J Immunol. 2006 Mar 1;176(5):3115-26
16493071
Mol Pharmacol. 1998 Jul;54(1):22-32
9658186
J Cell Biol. 1997 Sep 8;138(5):987-98
9281578
Neurochem Res. 2001 Sep;26(8-9):959-69
11699948
J Biol Chem. 2003 Apr 11;278(15):13309-17
12551918
Purinergic Signal. 2009 Mar;5(1):63-73
18568426
Purinergic Signal. 2007 Sep;3(4):389-98
18404452
Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):61-71
18336732
Neuroscience. 2001;102(3):593-602
11226696
J Neuropathol Exp Neurol. 2004 Jul;63(7):686-99
15290894
Pain. 2005 Apr;114(3):386-396
15777864
Biochem Biophys Res Commun. 2008 Dec 19;377(3):803-8
18938136
Pharmacol Ther. 2006 Jan;109(1-2):210-26
16169595
J Physiol. 1998 May 1;508 ( Pt 3):703-20
9518727
J Physiol. 1999 Apr 1;516 ( Pt 1):179-90
10066932
Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):168-75
12941474
Nature. 1988 Aug 25;334(6184):698-700
3137474
Eur J Neurosci. 2006 May;23(10):2824-8
16817887
Neuroreport. 2001 Aug 28;12(12):2619-22
11522936
Analyst. 2001 Aug;126(8):1257-60
11534589
Am J Physiol. 1993 Sep;265(3 Pt 1):C577-606
8214015
Invest Ophthalmol Vis Sci. 2004 Mar;45(3):1026-32
14985326
J Vet Med Sci. 2001 Apr;63(4):367-72
11346169
Am J Respir Crit Care Med. 2009 Feb 15;179(4):265-70
19201928
J Pharmacol Exp Ther. 2008 Dec;327(3):620-33
18772321
J Clin Invest. 2003 Feb;111(3):371-9
12569163
Brain Res. 2001 Oct 12;915(2):248-55
11595216
Mol Neurobiol. 2008 Oct;38(2):123-8
18704769
Behav Brain Res. 2009 Dec 1;204(1):77-81
19464323
Arch Biochem Biophys. 1993 Aug 15;305(1):54-60
7688203